Compiled all in one place, read news articles from each of the news categories, about drugs, the pharmaceutical industry, national and international awareness causes, scientific meetings, trending stories and epgonline.org headlines.

Site News

Added 23 hours ago Drug news

FDA approves Tibsovo to treat AML with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation.- Agios Pharma.

Agios Pharmaceuticals, Inc. has announced that Tibsovo (ivosidenib) was granted approval from the FDA for the treatment of adult patients...

Added 23 hours ago Drug news

FDA approval of Tibsovo to treat AML is based on Study AG120-C-001, NCT02074839.- Agios Pharma.

The FDA approval for Tibsovo (ivosidenib) was based on the clinical data from an open-label, single-arm, multicenter dose-escalation and expansion...

Added 23 hours ago Drug news

Successful Phase III study of Vyxeos compared to standard of care for AML is published in the Journal of Clinical Oncology.

Jazz Pharmaceuticals plc announced that data from the pivotal Phase III study of Vyxeos (daunorubicin and cytarabine) liposome for injection...

Added 23 hours ago Drug news

Verkazia is EU approved to treat severe vernal keratoconjunctivitis .- Santen Pharma.

Santen Pharmaceutical Co., Ltd. announced that the European Commission has granted marketing approval for DE-076C (Verkazia eye drop emulsion containing...

Added 23 hours ago Industry news

Boston Scientific to acquire Claret Medical and with it Sentinel Cerebral Embolic Protection System

Boston Scientific Corporation announced it has signed an agreement to acquire Claret Medical, Inc., a privately-held company that has developed...

Added 23 hours ago Industry news

PTC Therapeutics Inc. acquires Agilis Biotherapeutics and with it GT AADC a treatment for Aromatic L-Amino Acid Decarboxylase Deficiency.

PTC Therapeutics, Inc. announced that it has entered into an agreement to acquire Agilis Biotherapeutics, Inc., a biotechnology company advancing...

Added 1 day ago Drug news

Two Phase III trials, SEQUOIA and CEDAR for abicipar both the 8-week and 12-week treatment regimens met the pre-specified primary endpoint of non-inferiority to ranibizumab.- Allergan + Molecular Partners

Allergan plc and Molecular Partners a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin therapies, announced...

Added 1 day ago Drug news

Phase III VISIBLE 1 trial of subcutaneous Entyvio meets endpoint in ulcerative colitis.- Takeda.

Takeda has announced that the Phase III VISIBLE 1 trial of investigational subcutaneous formulation Entyvio (vedolizumab) for patients with ulcerative...

Added 1 day ago Drug news

CARMELINA trial reports on CV safety of Tradjenta in diabetes type 2 patients with CV risk.- Boehringer + Eli Lilly.

CARMELINA (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) met...

Added 1 day ago Drug news

The label for Eli Lilly's Trulicity is updated to show its safety and efficacy in type 2 diabetes with moderate to severe chronic kidney disease.

The U.S. label for Eli Lilly and Company's once-weekly Trulicity (dulaglutide) is updated to show the medicine's safety and efficacy...

Search all news articles